Table 1.
Demographics of Glioblastoma Multiforme (GBM) patients and healthy control cohorts.
| IDs | Age | Sex | Diagnosis | IDH | MGMT | EGFR | MET | TERT | CDKN2A |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 72 | F | GBM | WT | Methylated | Unamplified | Unamplified | Mutant | Loss |
| P2 | 41 | F | GBM | WT | Methylated | NK | NK | WT | Maintained |
| P3 | 52 | F | GBM | WT | Methylated | NK | NK | Mutant | Maintained |
| P4 | 73 | F | GBM | WT | Unmethylated | Unamplified | Unamplified | Mutant | Loss |
| P5 | 71 | M | GBM | WT | Unmethylated | Amplified | Amplified | WT | Maintained |
| P6 | 61 | F | GBM | WT | Unmethylated | Unamplified | Unamplified | WT | Maintained |
| P7 | 68 | F | GBM | WT | Unmethylated | Amplified | NK | Mutant | Maintained |
| P8 | 65 | F | GBM | WT | Methylated | Unamplified | Unamplified | WT | Loss |
| P9 | 74 | F | GBM | WT | Methylated | Unamplified | Amplified | WT | Maintained |
| H1 | NK | NK | - | - | - | - | - | - | - |
| H2 | 24 | F | - | - | - | - | - | - | - |
| H3 | NK | NK | - | - | - | - | - | - | - |
| H4 | NK | NK | - | - | - | - | - | - | - |
| H5 | 25 | M | - | - | - | - | - | - | - |
| H6 | 24 | F | - | - | - | - | - | - | - |
| H7 | 24 | F | - | - | - | - | - | - | - |
Abbreviations: GBM, glioblastoma; WT, wildtype; IDH, isocitrate dehydrogenase; EGFR, epidermal growth factor receptor; MET, MET proto-oncogene; TERT, telomerase reverse transcriptase; CDKN2A, Cyclin Dependent Kinase Inhibitor 2A; NK, not known.